Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Yissum Spins-Off Nanolymf to Advance Breakthrough Liver-Bypassing Oral Drug Delivery Technology

Abstract:
Yissum Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced the formation of Nanolymf, a biotechnology start up company dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs. Nanolymf was founded as a subsidiary of Shizim Ltd., a leading group of life science companies in Israel.

Yissum Spins-Off Nanolymf to Advance Breakthrough Liver-Bypassing Oral Drug Delivery Technology

JERUSALEM, Israel | Posted on December 20th, 2007

Nanolymf's technology was developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy and is exclusively licensed from Yissum. Per the terms of the agreement, Nanolymf has acquired exclusive rights and Yissum will receive royalties, sublicense fees, and an equity stake in Nanolymf.

Nava Swersky Sofer, CEO of Yissum stated, "The ability to deliver lipophilic drugs orally while bypassing specific potent barriers in the intestine and the liver carries tremendous potential. Prof. Benita, a seasoned inventor and entrepreneur and the founder of Novagali SA, one of Yissum's most promising spin-offs, has once again demonstrated his ingenuity in developing a novel mechanism addressing many unmet medical needs. Shizim, headed by Yossi Bornstein and encompassing, among its holdings, one of the leading clinical research organizations in Israel and the representation of one of the world's largest pharmaceutical companies, is an excellent partner for launching this new company."

Lipophilic drugs are poorly soluble in water, seriously limiting their bioavailability and clinical efficacy. In addition, when administrated orally 25% of these sensitive drugs cannot be absorbed because they activate an intestinal pump barrier and are metabolized in the intestines and liver. Therefore, currently many drugs present limited oral bioavailability or else are injected. Nanolymf developed a breakthrough controlled release drug delivery system that is able to bypass intestinal and liver metabolic filters, resulting in increased bioavailability following oral administration, without any alteration of the drug molecules. This unique system allows changing the route of administration of highly lipophilic drugs from injectable to oral with high bioavailability and low side effects without affecting the normal physiological activity of the metabolic filters. The patented technology was successfully tested on animals, resulting in 2.4 times higher bioavailability of the model drug - Tacrolimus - in large animals, and is now ready for starting clinical trials on humans.

Yossi Bornstein Nanolymf's Founder, CEO and Chairman added, "We are very excited with the potential of Nanolymf's technology to offer a significant breakthrough in the oral administration of many drugs and encouraged by the extraordinary pre-clinical results."

To date, Nanolymf has raised approximately $500,000 from private investors and is seeking to raise an additional $2M to fund initial clinical studies.

####

About Yissum Ltd.
Yissum was founded in 1964 to protect the Hebrew University’s intellectual property and commercialise it. $1 Billion in annual sales are generated by products based on Hebrew University technologies licensed out by Yissum. Ranked among the top technology transfer companies in the world, Yissum has registered 5000 patents covering 1400 inventions; licensed out 400 technologies and spun out 60 companies. Yissum’s business partners span the globe and include companies such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel, Teva and many more. For further information please visit www.yissum.co.il.

About Nanolymf

Nanolymf Ltd., a subsidiary of Shizim Ltd. a holdings group, is dedicated to change the route of administration of many highly lipophilic drugs from injectable to oral with high bioavailability and low side effects. The company has developed a breakthrough controlled release drug delivery system that is able to bypass intestinal and liver metabolic filters, resulting in increased bioavailability following oral administration, without any alteration of the drug molecules. For further information please visit www.shizim.com.

Nanolymf's senior management team includes Yossi Bornstein, CEO and Chairman and co-founder of Nanolymf. Mr. Bornstein is a highly respected entrepreneur with an outstanding record in the pharmaceutical industry. He was the General Manager of Bristol-Myers Squibb in Israel. He is the founder and owner of the Shizim Group. Mr. Bornstein served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (USISTC); consultant for the United States-Israel Science & Technology Foundation (USISTF); founder and committee member, of the Israel Life Science Industry Organization (ILSI); and founder of the Israel Technology Transfer Organization (ITTN).

Professor Simon Benita, Chief Scientist and co-founder of Nanolymf, is a well known researcher from the Hebrew University of Jerusalem who was granted the prestigious AAPS Fellows 2006 for professional excellence and outstanding scientific contribution as one of the world's leading researchers and authorities on polymeric microparticulate and lipid-based drug delivery systems, with a proved commercialization record. Prof. Benita is the founder of Novagali Pharma.

For more information, please click here

Contacts:
Yissum Ltd.
Tsipi Haitovsky, Media Liaison, +972-52-598-9892

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Production of Organometallic Frameworks in Least Possible Time September 23rd, 2014

Engineers show light can play seesaw at the nanoscale: Discovery is another step toward faster and more energy-efficient optical devices for computation and communication September 22nd, 2014

New chip promising for tumor-targeting research September 22nd, 2014

Twisted graphene chills out: When two sheets of graphene are stacked in a special way, it is possible to cool down the graphene with a laser instead of heating it up, University of Manchester researchers have shown September 22nd, 2014

Nanomedicine

Production of Organometallic Frameworks in Least Possible Time September 23rd, 2014

Engineered proteins stick like glue — even in water: New adhesives based on mussel proteins could be useful for naval or medical applications September 22nd, 2014

New chip promising for tumor-targeting research September 22nd, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

Announcements

Production of Organometallic Frameworks in Least Possible Time September 23rd, 2014

New chip promising for tumor-targeting research September 22nd, 2014

Twisted graphene chills out: When two sheets of graphene are stacked in a special way, it is possible to cool down the graphene with a laser instead of heating it up, University of Manchester researchers have shown September 22nd, 2014

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Acquisitions/Mergers/Splits

PEN Inc. Chairman, Scott Rickert, Will Webcast a Live Company Update September 25, 1 PM EDT September 17th, 2014

State University of New York Trustees Unanimously Approve SUNY Polytechnic Institute (SUNY Poly) as New Name for Merged SUNY CNSE / SUNYIT September 9th, 2014

PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014

Applied Nanotech Holdings, Inc. and NanoHoldings Inc. Complete Combination to Create PEN Inc.: New Company to Focus on Commercialization of Advanced Nanotechnology-Enabled Products; Scott Rickert Is Chairman and CEO September 2nd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE